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Abstract
Background: Nocturia has been independently associated with cardiovascular morbidity and all-cause mortality, but such
studies did not adjust for sleep-disordered breathing (SDB), which may have mediated such a relationship. Our aims were to
determine whether an association between nocturia and cardiovascular morbidity exists that is independent of SDB. We
also determined whether nocturia is independently associated with SDB.
Methodology/Principal Findings: In order to accomplish these aims we performed a cross-sectional analysis of the Sleep
Heart Health Study that contained information regarding SDB, nocturia, and cardiovascular morbidity in a middle-age to
elderly community-based population. In 6342 participants (age 63611 [SD] years, 53% women), after adjusting for known
confounders such as age, body mass index, diuretic use, diabetes mellitus, alpha-blocker use, nocturia was independently
associated with SDB (measured as Apnea Hypopnea index .15 per hour; OR 1.3; 95%CI, 1.2–1.5). After adjusting for SDB
and other known confounders, nocturia was independently associated with prevalent hypertension (OR 1.23; 95%CI 1.08–
1.40; P=0.002), cardiovascular disease (OR 1.26; 95%CI 1.05–1.52; P=0.02) and stroke (OR 1.62; 95%CI 1.14–2.30; P=0.007).
Moreover, nocturia was also associated with adverse objective alterations of sleep as measured by polysomnography and
self-reported excessive daytime sleepiness (P,0.05).
Conclusions/Significance: Nocturia is independently associated with sleep-disordered breathing. After adjusting for SDB,
there remained an association between nocturia and cardiovascular morbidity. Such results support screening for SDB in
patients with nocturia, but the mechanisms underlying the relationship between nocturia and cardiovascular morbidity
requires further study. MeSH terms: Nocturia, sleep-disordered breathing, obstructive sleep apnea, sleep apnea,
polysomnography, hypertension.
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Introduction
Sleep-disordered breathing (SDB) may lead to cardiovascular
morbidity due to repetitive episodes of complete or partial upper
airway obstruction [1,2]. The mechanisms underlying such
adverse cardiovascular effects are complex and are attributed, in
part, to increased cardiac (stretch or) transmural pressure
generated during occluded breathing, hypoxemia, and increased
sympathetic activity (due to hypoxemia and arousals from sleep)
[3]. Such pathophysiological mechanisms can also stimulate the
secretion of natriuretic hormones [4] and thereby cause nocturia.
Although previous case series and reports have reported nocturia
as a manifestation of SDB [5,6,7,8,9,10], a comprehensive and
systematic study of the association between nocturia and SDB in a
large community-based population has not been performed.
Moreover, nocturia per se may be associated with morbidity and
mortality, rather than merely reflecting a consequence of adverse
cardio-respiratory interactions [11]. Specifically, nocturia has been
independently associated with falls, hypertension, and all-cause
mortality in a study of elderly patients [12,13,14]. However, in
such cohorts assessing the relationship between nocturia and
hypertension, the investigators did not perform polysomnography
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6nor did they adjust for SDB as a confounder [15,16,17,18,19].
Moreover, cohort studies have demonstrated an association
between SDB and all cause mortality [20,21,22,23,24]. Hence, it
is unclear as to whether nocturia is independently associated with
hypertension, or whether such association may be attributable to
residual confounding by co-existent SDB.
Our primary aim was to determine the cross-sectional
associations between nocturia and cardiovascular morbidity exists
(hypertension, coronary artery disease, heart failure, and stroke)
that is independent of SDB in the Sleep Heart Health Study
(SHHS) cohort. We hypothesized that self-reported frequency of
nocturia is associated with prevalent hypertension and prevalent
cardiovascular disease after adjusting for co-existent SDB. An
additional aim was to determine whether nocturia is indepen-
dently associated with SDB. We hypothesized that SDB is
independently associated with self-reported frequency of nocturia
in a large cohort of middle-aged and older individuals.
Methods
Study Population
This report uses data from the Sleep Heart Health Study
(SHHS), a prospective multi-center cohort study that was
performed to assess whether SDB is a risk factor for cardiovas-
cular disease in middle-age and older adults. The SHHS had
been approved by the institutional review board at each
participating site. Informed written consent was obtained from
all participants. Details regarding the design and methodology
are available elsewhere [25,26]. Briefly, participants were
recruited from ongoing cohort studies, that included the
Cardiovascular Health Study [27], the Framingham Heart Study
Table 1. Participant Characteristics.
Variable Nocturia No nocturia P value
Age (years) 64.2610.5 61.2611.3 ,0.0001
Men (proportion) 56.7% 57.6% 0.49
Body Mass Index (Kg/m
2) 28.765.5 28.365.2 0.007
FEV1 (Liters) 2.6260.80 2.7763.3 0.02
Alcohol consumption
(drinks per night)
0 (0, 3) 0 (0, 4) 0.49
Diuretic intake (proportion) 17.0% 13.4% ,0.0001
Diabetes Mellitus
(proportion)
11.4% 10.0% 0.08
Alpha blockers (proportion) 6.1% 2.8% ,0.0001
AHI (4% hypopnea) 4.6 (1.6, 11.1) 5.7 (1.9, 13.9) ,0.0001
Patients with AHI .15
events/hr
23.2% 17.4% ,0.0001
Patients with AHI .10
events/hr
33.9% 27.3% ,0.0001
Patients with AHI .5
events/hr
39.8% 48.2% ,0.0001
Kg/m
2=kilogram/meter
2; FEV1=Forced expiratory volume; hr=hour;
proportions compared by Chi square; Mann-Whitney test for non-parametrics
(presented as median and interquartile range); unpaired t-test for parametric
variables (presented as mean 6 SD); AHI=apnea-hypopnea index.
doi:10.1371/journal.pone.0030969.t001
Figure 1. Proportions and numbers of patients with reported
frequency of nocturia. Participants were queried as to how often in
the prior year, did they awaken to go to the bathroom: never, rarely (1/
month or less), sometimes (2–4/month), often (5–15/month), and
almost always (16–30/month).
doi:10.1371/journal.pone.0030969.g001
Table 2. Variables Associated With Presence Of Nocturia.
{
Variable B (S.E.) P value 95% CI
AHI
{ 0.008 (0.001) ,0.0001 0.005, 0.01
AHI .15
* 0.18 (0.04) ,0.0001 0.12, 0.27
AHI .10
* 0.17 (0.04) ,0.0001 0.10, 0.24
AHI .5
* 0.14 (0.03) ,0.0001 0.07, 0.20
Age 0.015 (0.001) ,0.0001 0.013, 0.018
Body mass index 0.009 (0.003) 0.002 0.003, 0.014
Alcohol 0.005 (0.002) 0.046 0, 0.01
Diuretics
* 0.14 (0.04) 0.001 0.05, 0.22
Diabetes Mellitus
* 0.11 (0.05) 0.034 0.008, 0.20
a-blocker
* 0.51 (0.07) ,0.001 0.37, 0.65
FEV1 20.20 (0.01) 0.003 20.03, 20.01
Coffee 20.03 ,0.0001 20.04, 20.02
Soda 20.06 ,0.0001 20.09, 20.03
Tea 0.01 0.4 20.013, 0.04
Multiple regressions
1
AHI
{ 0.004 (0.001) 0.001 0.002, 0.007
AHI .15
* 0.12 (0.04) 0.007 0.03, 0.21
AHI .10
* 0.07 (0.04) 0.06 20.01, 0.15
AHI .5
* 0.07 (0.04) 0.04 0.0, 0.14
AHI=respiratory disturbance index; BMI=body mass index; FEV1=forced
expiratory volume in one second; CI=confidence interval;
*dichotomous variables;
{continuous variable.
1Multiple regression that adjusts for age, BMI, alcohol, diuretics, FEV1, a-blocker,
coffee and soda.
doi:10.1371/journal.pone.0030969.t002
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Disease [29], the Strong Heart Study [30], the Atherosclerosis
Risk in Communities Study [31], the Health and Environment
Cohort Study in Tucson, as well as three New York City cohorts
undergoing evaluation for the impact of psychosocial risk factors
on cardiovascular disease. Inclusion criteria included age $40
years and not having received positive airway pressure treatment
for sleep apnea, a tracheostomy, or supplemental oxygen.
Participants underwent unattended PSG at home between
December 1995 and January 1998.
Polysomnography
Polysomnography (PSG) was performed in an unattended
setting at home (Compumedics PS-2 system; Compumedics Pty.
Ltd, Abbotsville, Australia). Recordings included electroencepha-
logram (C3/A1 and C4/A2), right and left electrooculograms,
submental electromyogram, nasal/oral airflow recorded by
thermocouple (Protech, Woodenville, WA), rib cage and abdom-
inal movement recorded by inductive plethysmography, oxyhe-
moglobin saturation (SpO2) by pulse oximetry (Nonin, Minneap-
olis, MN), and electrocardiogram. Leg movements were not
recorded. Standardized techniques for sensor attachment and
quality assurance were used and have been previously described
[25].
PSG Scoring and Sleep Parameters
Scoring of sleep stages followed the guidelines of Rechtschaffen
and Kales and were performed at a centralized location [32].
Apnea was defined as complete or almost complete cessation of
airflow (,25% of baseline) and associated with 4% desaturation or
more. Hypopnea was defined as a decrease to less than 70% of
baseline on either inductance plethysmography channel or
thermocouple channels, for 10 seconds or longer and associated
with 4% desaturation or more. The apnea hypopnea index (AHI)
was calculated by computing the average number of apneas plus
hypopneas per hour of sleep.
Health and Demographic Data
Demographic information was obtained from the parent
cohorts. Participants’ weight was measured using a calibrated
scale at the time of PSG. Participants’ height was taken from
parent study data obtained within 3 years of the sleep study and
used to calculate the body mass index (BMI) (kg/m
2). Health
information was derived from several sources. Data related to
chronic medical conditions (such as diabetes mellitus) was obtained
from the parent cohorts. Current medications were recorded on
the night of the PSG. The SHHS Sleep Habits Questionnaire
incorporated the Epworth Sleepiness Scale.
An interviewer administered health interview on the night of the
PSG was used to obtain information pertaining to self-reported
prevalent cardiovascular disease, smoking and caffeine use. In the
Sleep Heart Health Study (SHHS), the interviewer asked if a
doctor had ever told the participant that she or he had angina,
heart attack, heart failure, or stroke and if the participant ever
underwent coronary artery bypass surgery or coronary angioplas-
ty. An ‘‘unsure’’ response was allowed for each item. We then
defined prevalent cardiovascular disease as a positive response to
one or more of the afore-mentioned conditions or procedures.
Figure 2. Association between nocturia and presence of sleep-disordered breathing based upon different apnea-hypopnea index
(AHI) thresholds are shown as odds ratio (symbol) and 95% confidence intervals (y-error bars). Odds ratios and respective confidence
intervals that were adjusted for confounders (left panel) and unadjusted for confounders (right panel) are shown. The x-axis of each panel represents
nocturia expressed as a dichotomous categorical variable (nocturia present or absent) by progressively increasing the threshold level of collapse from
‘rarely’ to ‘always’ to yield four different dichotomous variables for nocturia. The cluster of three symbols with corresponding error bars for each
definition of nocturia correspond to variable AHI thresholds for nocturia from left-to-right (.15, .10 and .5 per hour, respectively). For nocturia
defined as greater than rarely (closed triangle) only one adjusted odds ratio is shown (left panel) because multivariate regression was performed only if
univariate regression was significant at P,0.05 (see methods).
doi:10.1371/journal.pone.0030969.g002
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the questions about heart failure (which sometimes has a coronary
etiology) and stroke. Those who responded ‘‘No’’ to all of the
questions were considered free of cardiovascular disease. The
remainder (i.e., a combination of ‘‘no’’ and ‘‘Unsure’’ responses to
all of the items) were classified as unknown disease status and were
considered missing in these analyses. Data pertaining to certain
covariates such as chronic medical conditions (diabetes mellitus)
was collected from the parent cohort as long as such information
was collected within a 3 month window of the home sleep study. If
such covariate information pertaining to chronic medical condi-
tions was collected outside the 3-month window, then such
variables had to be re-ascertained during the interview. Hyper-
tension was considered present if the participant had a blood
pressure of at least 140/90 mm Hg on the night of the PSG, or
was currently being treated with antihypertensive medications.
Categorization and codification of nocturia variable
Data on nocturnal urinary frequency was obtained from the
SHHS Sleep Habits Questionnaire. Participants were queried as to
how often they awakened to go to the bathroom: never, rarely (1/
month or less), sometimes (2–4/month), often (5–15/month), and
almost always (16–30/month). For the purpose of analysis in this
study,nocturia wasanalyzedboth asa continuousvariableaswell as
a categoricalvariableaftercollapsingthegroups.Forthecontinuous
variable, we codified the five ordinal categories of nocturia in the
following manner: never=1; rarely=2, sometimes=3; often=4;
and almost always=5. Also, we collapsed this ordinal ‘nocturia’
variableintoadichotomouscategoricalvariable(nocturiapresentor
absent) by progressively increasing the threshold level of collapse
from ‘rarely’ to ‘often’ to yield 4 different dichotomous variables for
nocturia. Our rationale for such analytical methodology was the
following: first, nocturia is not usually defined by a particular
threshold volume or frequency of nocturia; second, by international
consensus, nocturia is simply defined as waking at night to void,
which implies that nocturia is a continuum from normal to a
bothersome or morbidity-associated abnormal condition [33]. We
subsequently used the dichotomous variable that was most strongly
associated with SDB for further analysis.
Statistical Analyses
Proportions were analyzed by x
2, and continuous variables were
compared by unpaired t-tests or the non-parametric equivalent
(Mann-Whitney) test. Logistic regression was used to calculate the
odds ratio (OR) of nocturia while comparing SDB categories and
adjusting for possible confounders. In these analyses, AHI was
categorized by commonly used clinical cutoff points (5, 10, and 15
per hour). Univariate and multivariate linear regressions with
nocturia expressed as a dependent linear variable was performed
in order to determine whether nocturia was associated with SDB.
Binary logistic regression was performed to identify significant
variables and all variables significant at P,0.05 level were
included as independent variables in multivariate logistic regres-
sion models (forced entry). All analyses were performed using
SPSS for Windows Version 12.0.1. Data are presented as mean 6
SD or median and interquartile range wherever appropriate.
Results
The characteristics of the patients with and without nocturia are
shown in Table 1. Patients with nocturia were older, had greater
body mass index (BMI), and were more likely to be receiving
diuretic agents or alpha-blockers (likely for prostatism). In 6342
participants (age 63611 [SD] years, 53% women) self-reported
levels of nocturia are depicted in Figure 1. In Table 2,
increasing severity of nocturia – expressed as an ordinal variable –
was associated with increasing severity of SDB, increasing age,
increasing BMI, greater alcohol consumption, diuretic intake,
presence of diabetes mellitus, lower lung function (measured as
forced expiratory volume in 1 second [FEV1]), greater sleep
fragmentation (time awake after sleep onset and arousals per hour
of sleep) and a-blocker ingestion. After adjusting for such
confounders, the association between nocturia and SDB remained
(Table 2). Collapsing the ordinal variable differently – in order to
identify the threshold level of nocturia frequency that was most
strongly associated with SDB – yielded two threshold levels (at
least 5 nights per month or at least 16 nights per month) that were
significantly associated with SDB (Figure 2). Using the former
definition (at least 5 nights per month), 3625 (57.1%) patients were
classified as having nocturia (Figure 1).
Relationship between nocturia and SDB
Univariate logistic regression identified the following covariates
associated with nocturia: greater age, higher body mass index,
lower forced expiratory volume in one second, ingestion of any
Table 3. Unadjusted And Adjusted Odds Ratios Of Variables
Associated With Nocturia.
II
Variable Unadjusted Odds Ratio (95% CI)
Univariate regressions
Age* 1.03 (1.02–1.03)
{{{
Gender{ 0.97 (0.87–1.07)
Body mass index{ 1.01 (1.00–1.02)***
Diabetes Mellitus1 1.16 (0.98–1.37)
Diuretic
I 1.33 (1.16–1.53)
{{{
Alcohol use** 1.008 (0.99–1.02)
Alpha blocker use{{ 2.25(1.72–2.93)
{{{
Coffee intake (cups per day) 0.95 (0.93, 0.97)
{{{
Tea intake (cups per day) 1.01 (0.97, 1.05)
Soda intake (cans per day) 0.91 (0.87, 0.95)
{{{
FEV1
{{ 0.88 (0.83–0.94)
{{{
AHI .15
11 1.44 (1.26–1.65)
{{{
AHI .10
11 1.36 (1.21–1.53)
{{{
AHI .5
11 1.25 (1.12–1.39)
{{{
Multivariate regressions@ Adjusted odds ratios
AHI .15
11 1.31 (1.13–1.51)
{{{
AHI .10
11 1.2 (1.06–1.36)
***
AHI .5
11 1.16 (1.03–1.30)***
@Adjusted for age, body mass index, diuretics, alpha-blockers, and FEV1.
FEV1=Forced expiratory volume in 1 second; AHI=apnea hypopnea index;
B=estimated coefficient; S.E.=standard error; CI=confidence intervals;
*per unit year age;
{compared to women;
{per unit Kg/m
2;
1compared to no history of diabetes mellitus;
Icompared to no diuretic intake;
**continuous variable (number of drinks per day);
{{compared to no alpha-blocker use;
{{per liter FEV1;
IIdichotomous variable. Nocturia was defined as ‘often’ (occurring at least 5
times per month).
***P,0.05;
{{{P,0.0001.
doi:10.1371/journal.pone.0030969.t003
Nocturia and Sleep Disordered Breathing
PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e30969diuretic, ingestion of alpha blocker agents, and the presence of
SDB based on a thresholds of 5, 10, or 15 events per hour for the
AHI (P,0.05)(Table 3). Presence of diabetes mellitus and
ingestion of alcohol also had a tendency to be associated with
nocturia (P=0.08; Table 3).
Multiple logistic regression, with nocturia as the dependent
variable, revealed that after adjusting for age, body mass index,
ingestion of diuretics, alcohol consumption, diabetes mellitus, and
alpha blocker agents, and FEV1, the presence of SDB was
independently associated with nocturia using all 3 cutoffs for AHI
(5, 10, or 15 per hour) with hypopneas requiring .4% oxygen
desaturation. However, statistical significance was not achieved for
AHI .5 per hour (Table 3).
Relationship between nocturia, hypertension, and
cardiovascular disease
Univariate logistic regression identified the following covariates
were associated with hypertension: nocturia, greater severity of
SDB (AHI with 4% oxygen desaturation; continuous variable),
greater age, higher body mass index, ethnicity, cigarette smoking,
time awake after sleep onset, arousals per hour of sleep, alcohol
ingestion, neck circumference, and waist-hip ratio (Table 4).
Using multiple logistic regression, nocturia was independently
associated with hypertension after adjusting for age, body mass
index, ethnicity, cigarette smoking, alcohol ingestion, neck
circumference, and waist-hip ratio, diuretics and severity of SDB
(AHI with hypopneas requiring at least 4% oxygen desaturation;
(Table 4).
Nocturia was independently associated with cardiovascular
disease and stroke after adjusting for SDB and other known
confounders for cardiovascular disease, whereas, nocturia was
associated with a reduced odds ratio for presence of heart failure
(Table 5). History of coronary artery disease was not associated
with presence of nocturia (table 5).
Polysomnographic changes and Sleepiness
Patients with nocturia displayed greater derangement of
polysomnographic measures than patients without nocturia
Table 4. Adjusted And Unadjusted Odds Ratios Of Associations with Hypertension.
Variable
Unadjusted Odds ratio
(95% CI)
Univariate regressions
Nocturia 1.44 (1.30–1.59)
{{{
Age 1.05 (1.05–1.06)
{{{
Body mass index 1.04 (1.03–1.05)
{{{
African-Americans* 0.55 (0.46–0.66)
{{{
Gender 1.08 (0.98–1.19)
Cigarette pack years{ 1.004 (1.002–1.006)
{{{
Alcohol 0.99 (0.99–1.00)
Neck circumference{ 1.06 (1.05–1.07)
{{{
Diabetes Mellitus1 2.4 (2.04–2.84)
{{{
AHI
I 1.02 (1.02–1.03)
{{{
Diuretics** 96.7 (62.5–149.6)
{{{
Waist-hip ratio{{ 8.49 (4.78–15.1)
{{{
Multivariate Regressions with variables adjusted for: Adjusted Odds Ratios
Diuretics, age, BMI, ethnicity, smoking, neck size, diabetes, waist-hip ratio (Model r
2=0.38)
Nocturia
{{ 1.23 (1.08–1.40)***
AHI, diuretics, age, BMI, ethnicity, smoking, neck size, diabetes, waist-hip ratio (Model r
2=0.38)
Nocturia
{{ 1.22 (1.06–1.40)***
AHI, diuretics, age, BMI, ethnicity, smoking, neck size, diabetes, waist-hip ratio, WASO
11 (Model r
2=0.39)
Nocturia
{{ 1.20 (1.04–1.38)***
AHI, diuretics, age, BMI, ethnicity, smoking, neck size, diabetes, waist-hip ratio, Arousals
II (Model r
2=0.39)
Nocturia
{{ 1.22 (1.06–1.39)***
BMI=body mass index; AHI=apnea hypopnea index; diabetes=diabetes mellitus; B=estimated coefficient; SE=standard error; CI=confidence intervals.
*African-Americans compared to all other races combined;
{per cigarette pack year;
{per inch neck circumference;
1compared to absence of diabetes mellitus;
Iper unit apnea-hypopnea index (.4% desaturation for hypopnea; continuous variable);
**compared to no diuretic;
{{per unit change in ratio.
11WASO=time awake after sleep onset;
IIArousals=arousal index expressed as arousals per hour of sleep;
{{Nocturia was defined as ‘often’ (occurring at least 5 times per month).
***P,0.05;
{{{P,0.0001.
doi:10.1371/journal.pone.0030969.t004
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efficiency and proportion of REM sleep, but had a higher arousal
index and were more hypoxemic. They also were subjectively
more sleepy on the basis of their Epworth Sleepiness Score.
Discussion
Nocturia was independently associated with SDB in a large
community-based sample of middle-aged and older subjects.
Although previous reports had identified nocturia as a manifes-
tation of SDB, such studies had used either a much smaller sample
size (ranging from 5 to 138 subjects) [5,6,7,8,9,34,35] or had
studied a sleep lab-based population [6,7,8,9,10,34,35]. Our study
findings are therefore more generalizable as we studied a large
community-based sample of middle-aged to older population.
Moreover, our cross-sectional study revealed a robust relationship
between nocturia and SDB after adjustment for many potential
confounders. The association with SDB has important implica-
tions to patient care and research. Primary care physicians and
urologists should consider SDB in the differential diagnosis of
patients who present with nocturia. In addition, the mechanistic
underpinning for the relationship between nocturia and SDB, viz.,
natriuretic peptides and the stimulus for release of such natriuretic
peptides by the adverse cardio-respiratory effects of SDB (hypoxia,
increased respiratory effort [increased transmural pressure], and
arousals from sleep) and rostral fluid shifts may be worthy of
further research [36].
In our study, we also show that nocturia was independently
associated with prevalent hypertension, cardiovascular disease,
and stroke. Such an association was independent of co-existent
SDB measured by the AHI (Tables 4 and 5). Previous studies
have demonstrated an association between nocturia and cardio-
vascular morbidity, however, none of these studies measured or
adjusted for co-existent SDB [12,15,16,17,18,19]. Therefore, prior
to this report, whether nocturia was associated with hypertension
independent of co-existent SDB was unclear.
The association between nocturia and cardiovascular morbidity
raises some intriguing questions. First, what is the mechanism
underlying the association between nocturia and cardiovascular
morbidity? When considering this question, we should note that
the association between hypertension and nocturia was also
independent of the effects of diuretics (Table 4). One potential
postulated mechanism for the association between nocturia and
cardiovascular morbidity has been the adverse hemodynamic
changes associated with the stress of nocturnal awakenings [37]. It
is conceivable that nocturia, by virtue of disrupting sleep and
causing insufficient sleep, may lead to adverse cardiovascular
effects. There is an evolving, large body of literature concerning
the effects of poor or insufficient sleep on increased blood pressure,
glucose intolerance, and inflammation, which, may in turn, lead to
adverse cardiovascular morbidity [38]. In our report, however,
while sleep duration and efficiency were statistically lower in
subjects experiencing nocturia (when compared to subjects without
nocturia) the difference was small (Table 6). Such data would
suggest that mechanisms other than insufficient sleep may be
responsible for the association between nocturia and cardiovascu-
lar morbidity. Moreover, the multivariate regressions revealed that
nocturia was associated with cardiovascular disease independent of
sleep fragmentation measured as time awake after sleep onset or
arousals per hour of sleep (tables 4 and 5). Such findings would
Table 5. Adjusted Odds Ratios Of Associations Between
Nocturia and Prevalent Cardiovascular Morbidity.
Variable 95% CI
Cardiovascular disease
Adjusted for cardiovascular risk factors
* 1.23 (1.03–1.46)
{
Adjusted for cardiovascular risk factors and SDB
{ 1.26 (1.05–1.52)
{
Adjusted for cardiovascular risk factors, SDB, WASO
1 1.26 (1.05–1.53)
{
Adjusted for cardiovascular risk factors, SDB, arousals
I 1.28 (1.05–1.54)
{
Coronary artery disease
Adjusted for cardiovascular risk factors
* 1.14 (0.95–1.37)
Adjusted for cardiovascular risk factors and SDB
{ 1.12 (0.92–1.36)
Adjusted for cardiovascular risk factors, SDB, WASO
1 1.12 (0.92–1.36)
Adjusted for cardiovascular risk factors, SDB, arousals
I 1.14 (0.93–1.39)
Heart failure
Adjusted for cardiovascular risk factors
* 0.72 (0.48–1.08)
Adjusted for cardiovascular risk factors and SDB
{ 0.59 (0.38–0.92)
{
Adjusted for cardiovascular risk factors, SDB, WASO
1 0.58 (0.37–0.91)
{
Adjusted for cardiovascular risk factors, SDB, arousals
I 0.57 (0.36–0.90)
{
Stroke
Adjusted for cardiovascular risk factors
* 1.39 (1.01–1.91)
{
Adjusted for cardiovascular risk factors and SDB
{ 1.62 (1.14–2.30)
{
Adjusted for cardiovascular risk factors, SDB, WASO
1 1.61 (1.13–2.29)
{
Adjusted for cardiovascular risk factors, SDB, arousals
I 1.67 (1.16–2.40)
{
*Adjusted for age, gender, race, smoking, diabetes mellitus, hypertension,
systolic blood pressure, body mass index, total cholesterol, and high density
lipoprotein levels.
{Adjusted for sleep-disordered breathing (SDB; measured as apnea-hypopnea
index) in addition to other confounders listed
*. Nocturia was defined as ‘often’
(occurring at least 5 times per month).
1WASO=time awake after sleep onset;
Iarousal index expressed as arousals per hour of sleep;
{P,0.05.
doi:10.1371/journal.pone.0030969.t005
Table 6. Polysomnographic variables and subjective
sleepiness.
Polysomnography
Variable Nocturia
No
Nocturia P value
Sleep Latency (min)* 16.5 (9.5, 28.0) 16.5 (9.5, 29.5) 0.52
Sleep time (min) 365 (317, 404) 367 (322, 408) 0.06
Total sleep period (min) 448 (405, 482) 440 (396, 477) ,0.0001
Sleep efficiency (%)* 82.8 (75.4, 88.0) 85.1 (77.4, 90.1) ,0.0001
Wake after sleep onset (min) 55.5 (34.0, 87.0) 43.5 (26.5, 76.5) ,0.0001
NREM Stage 1 (%) 4.6 (2.8, 7.2) 4.5 (2.8, 7.1) 0.32
NREM Stage 2 (%) 57.5 (49.3, 65.4) 57.2 (49.3, 64.9) 0.30
NREM Stage 3 & 4 (%) 16.7 (8.2, 25.7) 17.0 (8.2, 24.6) 0.36
REM (%) 19.8 (15.4, 23.7) 20.5 (16.5, 24.3) ,0.0001
REM latency (min) 75.0 (56.5, 111.0) 72.5 (56.0, 100.5) 0.006
Arousal Index 17.3 (12.4, 24.3) 16.2 (11.6, 23.0) ,0.0001
Time spent SpO2 ,90% 0.28 (0.01, 2.35) 0.17 (0.0, 1.55) ,0.0001
Time spent SpO2 ,85% 0.0 (0.0, 0.08) 0.0 (0.0, 0.03) ,0.0001
Epworth sleepiness score 8 (5, 11) 6 (4, 10) ,0.0001
Min=minutes, %=percentage; NREM=non-rapid eye movement sleep;
REM=rapid eye movement sleep; SpO2=oxygen saturation by pulseoximetry;
*less than full compliments of sample size (3688 to 5837). Nocturia was defined
as ‘often’ (occurring at least 5 times per month).
doi:10.1371/journal.pone.0030969.t006
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disease is independent of known associations between adequate
sleep and cardiovascular disease [39].
Second, different cardiovascular morbidities expressed diver-
gent relationships with the presence of nocturia. Nocturia was
associated with an increased risk for hypertension, cardiovascular
disease, and stroke, whereas, presence of nocturia appeared to be
protective against heart failure (Table 5). Conceivably, nocturia
could reduce circulating blood volume and reduce cardiac preload
in patients with heart failure. However, such reasoning would be
at odds with data suggesting that the up-regulation of the
neurohormonal process underlying generation of nocturia –
natriuretic peptides – is associated with increased cardiovascular
mortality [40,41]. Such data may in turn be reconciled by
evidence suggesting that certain polymorphisms in natriuretic
peptides may be associated with reduced bioactivity of such
natriuretic hormones and consequently can influence outcomes in
heart failure [42]. We realize that the effects of residual
confounding cannot be excluded as a potential cause for such an
association. Clearly, the relationship between natriuretic peptides,
nocturia, and cardiovascular outcomes is complex and needs more
research.
The findings of this report should be considered in light of a
number of limitations. First, the association between nocturia and
SDB does not necessarily imply a cause-effect relationship based
on our data. However, other studies have demonstrated the
improvement of nocturia following continuous positive airway
pressure therapy and can attribute nocturia – at least in part – to
SDB [34,35,43]. Second, our study did not consider concomitant
measures relevant to nocturia such as daily water intake or diurnal
variation in urine production. Conceivably, greater ingestion of
fluids in patients with SDB who suffer from dry throat sensation
may play a role in the observed association between nocturia and
SDB. Third, we used AHI as the primary measure of the insults
imposed by SDB and did not consider a composite index that
included hypoxia and arousals – both mechanistically implicated
in the causation of nocturia by SDB. However, arousals alone have
not always been shown to be closely associated with cardiovascular
morbidity. Fourth, our report could have been strengthened by
accounting for the confounding influence of kidney disease, which,
through the loss of renal concentrating ability may lead to polyuria
and accompanying nocturia. However, in the SHHS study, while
the individual sub-cohorts had different measures relating to
kidney function that were obtained at different points in time,
there was not a uniform measure of kidney function for the entire
SHHS cohort obtained at the same time relative to the SHHS
protocol. We did find that measures of hypoxemia (number of
oxygen desaturations per hour and time spent below 90%) were
indeed associated with nocturia (data not shown). However, as
anticipated, such hypoxemia variables and the AHI were closely
correlated. Therefore we chose to only use the measure with the
stronger association with nocturia in our regression models – viz.,
apnea-hypopnea index. Lastly, the study variables regarding
nocturia and cardiovascular disease were based upon self-reported
cross-sectional data obtained at enrollment. Nocturia was not
measured from urine volume and the presence of cardiovascular
disease (other than hypertension) was not cross-referenced against
patient medical records. However, because of the difficulty in
measuring overnight nocturnal urine production, nocturia has
been defined quite simply by international consensus as just
waking at night to void [33].
In conclusion, nocturia is independently associated with sleep-
disordered breathing. After adjusting for SDB, there remained an
association between nocturia and cardiovascular morbidity. Such
results support screening for SDB in patients with nocturia, but the
mechanisms underlying the relationship between nocturia and
cardiovascular morbidity require further study. These data suggest
that clinicians should be cognizant of the association between
nocturia and SDB, and consider screening for SDB in patients
with recalcitrant nocturia.
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